Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.

@article{Galling2016SafetyAT,
  title={Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.},
  author={Britta Galling and A. C. Solis Roldan and Liz Rietschel and Katsuhiko Hagi and Frozan Walyzada and Wei Zheng and Xiao-lan Cao and Y. H. Xiang and John M. Kane and Christoph U Correll},
  journal={Expert opinion on drug safety},
  year={2016},
  volume={15 5},
  pages={591-612}
}
INTRODUCTION Antipsychotic co-treatment is common in schizophrenia, despite lacking evidence for its efficacy and safety. Areas: We conducted a systematic search of PubMed/PsycInfo/CJN/WangFan/CBM without language restrictions from database inception until 05/25/2015 for randomized trials comparing antipsychotic monotherapy with antipsychotic co-treatment in ≥20 adults with schizophrenia reporting meta-analyzable adverse events (AEs) data. Meta-analyzing 67 studies (n=4,861, duration=10.3±5.2… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS